The Reflux Esophagitis (Gastroesophageal Reflux Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Reflux Esophagitis (Gastroesophageal Reflux Disease). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued products.

GlobalData tracks 42 drugs in development for Reflux Esophagitis (Gastroesophageal Reflux Disease) by 34 companies/universities/institutes. The top development phase for Reflux Esophagitis (Gastroesophageal Reflux Disease) is phase i with 20 drugs in that stage. The Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline has 42 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline products market are: Korea United Pharm, Addpharma and Xiamen Encheng Pharmaceutical.

The key targets in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline products market include Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K(+) ATPase Subunit Alpha or Proton Pump or ATP4A or EC 7.2.2.19), Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1), and Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2).

The key mechanisms of action in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline product include Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K(+) ATPase Subunit Alpha or Proton Pump or ATP4A or EC 7.2.2.19) Inhibitor with 12 drugs in Pre-Registration. The Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline products include three routes of administration with the top ROA being Oral and two key molecule types in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline products market including Small Molecule, and Monoclonal Antibody.

Reflux Esophagitis (Gastroesophageal Reflux Disease) overview

Gastroesophageal reflux disease (GERD) refers to a condition where the liquid content of the stomach refluxes into the esophagus. It is a chronic condition. The symptoms of GERD are nausea, heartburn, and vomiting. The predisposing factors include eating large meals, which can cause the lower esophageal sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food, and certain drugs.

For a complete picture of Reflux Esophagitis (Gastroesophageal Reflux Disease)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.